• Arsenic, MMP-2/MMP-9, and BBB Cognitive Injury

  2026-09-11

  The reference study links chronic sodium arsenite exposure in male mice to blood-brain barrier disruption, hippocampal neuronal apoptosis, and impaired learning and memory through an MMP-2/MMP-9-associated pathway. Its doxycycline hyclate intervention provides pharmacological evidence that preserving barrier integrity may reduce arsenic-related cognitive dysfunction, while also highlighting the limits of interpreting a pleiotropic matrix metalloproteinases inhibitor as a selective mechanistic probe.

• GDC-0068: A Signal-Deconvolution Tool

  2026-09-10

  GDC-0068 (RG7440) is a selective pan-AKT inhibitor for dissecting PI3K/Akt/mTOR signaling, genotype-dependent vulnerability, and treatment-induced feedback. This article presents an assay-centered framework that connects Akt perturbation with spatially resolved mTORC1 biology.

• SAR405: Reliable Vps34 Inhibition in Cell Assays

  2026-09-10

  This scenario-based guide explains how SAR405 (SKU A8883) can clarify autophagy, vesicle-trafficking, and lysosomal phenotypes that are often obscured in cell viability assays. It covers experimental design, reagent handling, interpretation, and practical criteria for selecting a well-characterized Vps34 inhibitor.

• Pseudo-UTP for mRNA Synthesis Workflows

  2026-09-09

  Pseudo-UTP enables controlled pseudouridine incorporation during in vitro transcription, supporting RNA stability enhancement, translation studies, and innate-immune profiling. This practical guide covers substitution design, assay controls, optimization, and the limitations that matter for mRNA vaccine development and gene therapy RNA modification.

• Melittin in GPCR and Glioblastoma Research

  2026-09-09

  Melittin is a bioactive peptide for dissecting Gs/Gi-dependent signaling, migration, apoptosis, and lipid-linked mechanisms in glioblastoma models. This guide converts the miR-18a/ALOXE3 findings into a controlled workflow that separates acute signal transduction from cytotoxicity and ferroptosis-related effects.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-08

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator in colorectal cancer. By linking NAT1-dependent ENO1 acetylation to lactate-driven TRAF6 activation and PD-L1 stabilization, the work provides a mechanistic explanation for how tumor metabolism can shape immune checkpoint responses.

• Grazoprevir/Elbasvir: Evidence from HCV Therapy

  2026-09-07

  The reference review explains how complementary NS3/4A protease and NS5A inhibition established grazoprevir/elbasvir as an interferon-free strategy for chronic HCV infection. Its practical significance lies in consistently high virologic response, applicability to difficult-to-treat populations, and a framework for evaluating resistance, treatment duration, and drug interactions.

• Silk Fibroin–Ce6 Films for Infected Wound Healing

  2026-09-07

  The reference study develops an aligned silk fibroin electrospun film conjugated with Chlorin e6 (Ce6) for near-infrared photodynamic treatment of Staphylococcus aureus-infected wounds. Its importance lies in combining rapid reactive oxygen species generation with anisotropic cell-guidance properties and later-stage macrophage M2 polarization, linking infection control with tissue repair.

• Amikacin (BAY416651): From Mechanism to Translation

  2026-09-05

  A translational perspective on Amikacin (BAY416651), connecting 30S ribosome engagement, resistance-mechanism studies, and targeted delivery into mycobacterial granulomas.

• BRD4 Inhibition Amplifies Erastin-Induced Ferroptosis

  2026-09-05

  The reference study identifies BRD4 inhibition as a broadly active sensitizer of erastin-induced ferroptosis across several cellular models. Its data connect increased reactive oxygen species with reduced FSP1 expression, providing a mechanistic rationale for combining BET inhibition with ferroptosis-based strategies in cancer biology research.

• Proteinase K for Fungal EV Assay Design

  2026-09-04

  Proteinase K is more than a routine DNA extraction reagent: it can help researchers design cleaner, more interpretable fungal extracellular-vesicle assays. This article connects its proteolytic mechanism and matrix tolerance with a recent Candida albicans study while clearly separating established evidence from workflow recommendations.

• GDC-0068 (RG7440) Pan-AKT Inhibitor

  2026-09-04

  GDC-0068, also called RG7440, is an ATP-competitive pan-AKT inhibitor with activity against Akt1, Akt2, and Akt3. Product data support its use for studying PI3K/Akt/mTOR signaling, tumor-cell proliferation, cell-cycle control, and tumor models with PTEN loss or PI3K alterations.

• PF-04971729 Workflow for SGLT2 Research

  2026-09-03

  Ertugliflozin (PF-04971729) supports more than a standard glucose-uptake assay: it can connect SGLT2-mediated transport, metabolic phenotyping, cardiovascular endpoints, and exploratory mucosal-repair models. This practical guide covers dosing design, solvent control, translational assay selection, and troubleshooting for diabetes mellitus research.

• Axitinib Workflows for VEGF Signaling Assays

  2026-09-02

  Build more informative angiogenesis and cancer biology experiments with Axitinib (AG 013736), from receptor-proximal phospho-signaling assays to viability and xenograft study design. The workflow separates growth suppression from true cell killing while addressing solubility, timing, controls, and translational limits.

• sEV CD147 Drives HCC Angiogenesis via PI3K/Akt

  2026-09-02

  Huang et al. identified CD147-positive small extracellular vesicles as both a circulating HCC-associated signal and a functional mediator of endothelial angiogenesis. Their integrated clinical, cellular, and Matrigel plug experiments connect vesicle-associated CD147 with VEGFA induction through PI3K/Akt, providing a mechanistic framework for biomarker development and pathway validation.

8243 records 1/550 page Next 12345 下5页 Last page